Great Debates and Updates in Hematologic Malignancies

30. 4. 2010 - 1. 5. 2010, Westin New York Times Square, New York, New York, USA

Registrace

Program konference

Friday, April 30, 2010

8:00 am
Introduction

8:10 am
Acute Leukemia Session
Debate: Is chemotherapy still useful for APL in the era of ATRA and arsenic trioxide?
Harold P. Erba, MD, PhD
Gary Schiller, MD

8:35 am
Debate: What is the most appropriate and effective therapy for elderly AML patients?
Gary Schiller, MD, FACP
Harold P. Erba, MD, PhD

9:00 am
Emerging novel and promising therapeutic agents for AML
Stephen Nimer, MD

9:25 am
Coffee break

9:45 am
Lymphoma Session I
Debate: Should the results of interim PET scans change the planned management of advanced hodgkins lymphoma or diffuse large B-cell lymphoma?
Morton Coleman, MD, FACP
Craig Moskowitz, MD

10:10 am
Debate: Should surveillance CT scans be performed on DLBC lymphoma patients who achieve a CR from frontline therapy?
Andrew D. Zelenetz, MD, PhD
Peter Martin, MD

10:35 am
Debate: What is the most appropriate second line therapy for advanced follicular lymphoma patients who relapse following frontline R-CHOP?
Craig Moskowitz, MD
Andrew D. Zelenetz, MD, PhD
John P. Leonard, MD

11:05 am
What is the most appropriate management for stage I follicular lymphoma in a young patient - deciding when and with what to initiate therapy?
John P. Leonard, MD

11:35 am
Lunch

12:40 pm
Myeloma Session I
Debate: Since novel agents appear to abrogate the negative impact of poor risk cytogenetics, are cytogenetics by FISH still a necessary part of risk stratification for newly diagnosed multiple myeloma patients?
Sagar Lonial, MD
S. Vincent Rajkumar, MD

1:05 pm
Debate: What is the most appropriate frontline regimen for transplant ineligible myeloma patients?
Steven P. Treon, MD, PhD
Sagar Lonial, MD
S. Vincent Rajkumar, MD

1:30 pm
Debate: How should bisphosphonates be utilized in multiple myeloma patients responding to frontline therapy?
Paul G. Richardson, MD
Robert Z. Orlowski, MD, PhD

1:55 pm
Debate: For newly diagnosed SCTeligible myeloma patients the most appropriate induction therapy is: Sagar Lonial, MD
Paul G. Richardson, MD
Shaji Kumar, MD

2:35 pm
Coffee break

2:55 pm
CML Session
Debate: What is the best tyrosine kinase inhibitor for frontline therapy of CML?
Gail J. Roboz, MD
Hagop M. Kantarjian, MD

3:25 pm
Debate: What is the most appropriate salvage therapy for post-imatinib failure in CML?
Jorge E. Cortes, MD
Stephen Nimer, MD

3:55 pm
Evolving and promising therapeutic strategies for post-TKI failure in CML
Hagop M. Kantarjian, MD

4:20 pm
Adjourn

Saturday, May 1, 2010

8:05 am
CLL Session
Debate: FCR is the best frontline therapy for CLL patient ˇÝ65 years of age
Susan OˇŻBrien, MD
Asher Chanan-Khan, MD

8:30 am
Debate: How prominent should the roles of lenalidomide, bendamustine and ofatumumab be in the frontline therapy of CLL?
Susan OˇŻBrien, MD
Asher A. Chanan-Khan, MD

8:55 am
Myeloproliferative neoplasm session
Moderator: Richard T. Silver, MD

How I deal with the difficult questions in the management of Essential Thrombocythemia
Ruben A. Mesa, MD

9:25 am
What is the role of allogeneic transplantation in myeloproliferative neoplasms
Jorge E. Cortes, MD
Ruben A. Mesa, MD

9:50 am
Coffee break

10:10 am
Myeloma Session II
How I manage multiple myeloma patients who present with significant pre-existing illnesses or serious complications of the myeloma:
Rafael Fonseca, MD
Shaji Kumar, MD
S. Vincent Rajkumar, MD

10:50 am
Debate: For newly diagnosed multiple myeloma patients who relapse from a ˇÝVGPR response more than 12 months following frontline therapy, what is the best salvage strategy?
Robert Z. Orlowski, MD, PhD
Rafael Fonseca, MD

11:15 am
The next great therapeutic challenge in multiple myeloma: Designing novel agents and combinations to overcome myeloma cell resistance to proteasome and immunomodulatory agents
Paul G. Richardson, MD

11:40 am
Debate: Do nucleoside analogues still have a role in the frontline therapy of symptomatic Waldenstroms Macroglobulinemia?
Shaji Kumar, MD
Steven P. Treon, MD, PhD

12:10 pm
Lunch

1:10 pm
Lymphoma Session II
Emerging and promising novel agents for B-cell and T-cell lymphomas
Owen A. OˇŻConnor, MD, PhD

1:40 pm
Debate: Should treatment for limited stage non-bulky hodgkins lymphoma include radiation therapy?
Peter Martin, MD
Morton Coleman, MD, FACP

2:05 pm
Coffee break

2:25 pm
MDS Session
Moderator: Richard T. Silver, MD

Debate: What is the best therapy for MDS patients with deletion 5q?
Gail J. Roboz, MD
Guillermo Garcia-Manero, MD

2:50 pm
Debate: What is the best frontline therapy for intermediate-2 and high risk MDS?
Gail J. Roboz, MD
Jorge E. Cortes, MD

3:15 pm
Novel and evolving therapeutic strategies for MDS
Guillermo Garcia-Manero, MD

3:40 pm
Summary

3:50 pm
Adjourn

Kontakt: meetings@imedex.com

Web: http://www.imedex...LMN_12_3_0912_3_20

  • Sdílejte na:
    • Facebook
    • Twitter
    • Del.icio.us
    • Digg
    • Google
    • Reddit
    • StumbleUpon
    • Live